Skip to main content
Premium Trial:

Request an Annual Quote

Benitec Licenses Expressed RNAi Tech to Calimmune

Premium

Benitec Biopharma said this week that it has non-exclusively licensed its expressed RNAi technology to Calimmune for use in developing an RNAi-based HIV/AIDS treatment.

The deal covers the use of Benitec's technology against up to three viral and cellular genes identified as having therapeutic potential against HIV, Benitec said.

Additional terms of the deal were not disclosed.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.